Nr. 13145 Form

Central Laboratory with Blood Bank

Jauchgasse 25, 1030 Vienna



Version: 2

Valid from: 02.12.2020

Validation of AMP Rapid Test SARS-CoV-2 Ag

Product description: Rapid Test for detection of SARS-CoV-2 Antigen

Clinical value: Pre-testing of patients

For faster transfer or initiation of therapy, less floating beds for patients without COVID-symptoms or with

negative antigen test Screening of employees

Finding asympomatic, infectious employees

Manufacturer: AMEDA Labordiagnostik GmbH, Krenngasse 12, 8010 Graz

Scientific literature

edited by:

Dr. A Voill-Glaninger

PRE-ANALYTICS

Sample material required: Nasopharyngeal swab

Sample preparation: According to instructions for use

Pre-analytical peculiarities: Correct pre-analytics is very important to promote

sensitivity (deep smear, exact sample preparation in the

extraction buffer)

Patient preparation: None

EVALUATION

Responsible for Evaluation:

Laboratory specialist: Dr. A Voill-Glaninger, Dr. René Zadnikar

BA (execution): Nursing team in central emergency room

Evaluation:

Number of patient samples: 200

Reference method: PCR Test

Evaluation started: 02.11.2020 **Final report:** 02.12.2020

Created by: Approved by : Team (Coord.) Approved by

Printed: 06.12.2020 16:49:00 Page 1 of 2

Results:

Assessment of sensitivity:	with averaged ct - values, if 2 available
----------------------------	---

Viral load 100.000 ct 26,2: 100% Viral load 100% 50.000 ct 28,0: Viral load ct 30,0: 90% 10.000 Viral load 90% 5.000 ct 31,0:

Assessment of specificity: 100% (0 FP of 59 confirmed by PCR)

Duration of investigation: appr. 20 minutes incl. collection of swab sample

Practicability: as usual for rapid tests

Assessment of results by laboratory specialist and biomedical analyst:

AMP Rapid Test SARS-CoV-2 Ag shows significantly better sensitivity and specificity, especially in the range of relevant viral load, than three antigen tests from mayor international suppliers, which were also evaluated by WiGev (one alternative antigen test evaluated in-house and in Clinic Favoriten, two others evaluated Clinic Favoriten and Clinic Hitzing [data inspected]). Furthermore, the test is also offered as a combined test together with Influenza A/B and, as a product from an Austrian manufacturer, offers a high level of security in respect to availability and delivery time.

Conclusion:

Approval for pre-testing of patients and screening of employees with immediate effect and for preferred use.

Doz. Dr. Astrid Voill-Glaninger

Created by: Team (Coord.) Approved by : Management